283 related articles for article (PubMed ID: 26291199)
1. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Asaki T; Kuwano K; Morrison K; Gatfield J; Hamamoto T; Clozel M
J Med Chem; 2015 Sep; 58(18):7128-37. PubMed ID: 26291199
[TBL] [Abstract][Full Text] [Related]
2. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
[TBL] [Abstract][Full Text] [Related]
3. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
[TBL] [Abstract][Full Text] [Related]
4. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
[TBL] [Abstract][Full Text] [Related]
5. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
6. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
7. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA; Chin KM
Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
[TBL] [Abstract][Full Text] [Related]
8. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
[TBL] [Abstract][Full Text] [Related]
11. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
Kuwano K; Hashino A; Asaki T; Hamamoto T; Yamada T; Okubo K; Kuwabara K
J Pharmacol Exp Ther; 2007 Sep; 322(3):1181-8. PubMed ID: 17545310
[TBL] [Abstract][Full Text] [Related]
12. Selexipag for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N; Lang IM
Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
[TBL] [Abstract][Full Text] [Related]
13. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
14. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Morrison K; Ernst R; Hess P; Studer R; Clozel M
J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124
[TBL] [Abstract][Full Text] [Related]
15. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
[TBL] [Abstract][Full Text] [Related]
16. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
18. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Bruderer S; Hurst N; Kaufmann P; Dingemanse J
Pharmacology; 2014; 94(3-4):148-56. PubMed ID: 25277144
[TBL] [Abstract][Full Text] [Related]
19. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
20. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
